Sarepta Therapeutics Zooms Higher on Early Data Rally Promising
Sarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Budget calculator numbers can be opaque. Learn what they mean and how to translate them into concrete next steps.
17,878 articlesSarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Big banks are signaling a shift in U.S. stocks. This article breaks down three core reasons behind the downgrade and ...
Oil traders are weighing a hypothetical '$200 trump radar' scenario as prices approach extreme levels. This report ex...
When markets wobble, resilient essentials stocks shine. Meet three proven picks that have stood the test of time: Pro...
Defiance’s 2X inverse ETF tied to SMCI confronts a classic risk now that SMCI has reported after hours. The fund’s da...
The AI boom isn’t over yet, according to seasoned investor Paul Tudor Jones Says. This piece breaks down why the rall...
If your Airbnb business feels stuck, you might be leaving money on the table. This guide reveals six practical ways a...
Political rhetoric can shake markets and impact wallets. This article breaks down how trump’s “election integrity arm...
Analysts lean bullish on Apollo Global Management after a flurry of dealmaking, with elevated price targets and visib...
AI growth is fueling demand for data infrastructure, but investors still want reliable income. This article explains ...
Could XRP break the $5 barrier by 2026? This article breaks down the drivers, timelines, and practical steps for inve...
OKX is close to purchasing a 20% stake in Coinone, a leading South Korean crypto exchange. The deal, still under regu...